

Title: Development of a Biochip-based Continuous Metabolic Monitoring Patch

Dr. Idan Tamir, CEO QuLab Medical

- **Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.**

QuLab Medical is an innovative medical technology company pioneering the development of the first wearable Continuous Metabolic Monitoring (CMM) patch platform. This platform enables real-time continuous monitoring of several key metabolites in parallel in a single patch. Fusing the data from the monitoring of these metabolites, namely glucose, lactate and ketones – as the first line, using AI tools, provides unprecedented insight to the interplay between different metabolic pathways. Such an integrated and individualized approach to multi-metabolite monitoring is expected to revolutionize the way we understand disease development, progression and treatment. The company has established collaborations with key chip manufacturers and medical device companies.

- **Core Technology What is the technology, its uniqueness, and its value proposition?**

The company has developed wafer-level production capabilities, CMOS and MEMS-based sensor fabrication process, proprietary formulations for effective enzyme immobilization, and picoliter printing technology for sensor functionalization, ensuring scalability and manufacturability.

- **Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.**

QuLab Medical's is developing a Continuous Lactate Monitoring (CLM) patch for athletes as its first product. Despite the rapid growth of the sports, fitness and wellness market, real-time metabolic monitoring remains a critical gap. Traditional lactate testing requires frequent painful finger-prick blood sampling, limiting its applicability in real-world training and wellness. The absence of continuous lactate monitoring leads to suboptimal training, increased risk of overtraining injuries, and inefficient recovery strategies. No commercially available Continuous Lactate Monitor (CLM) exists, creating a major unmet market opportunity. QuLab's CLM patch has been successfully validated through in-vitro testing, animal models, and FIM human trials, confirming its safety, stability, and strong correlation between CLM and capillary periodic blood lactate measurements.

- **Business Strategy Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.**

The Total Addressable Market for continuous multi-metabolic monitoring is projected in the billions, creating new market opportunities within and beyond the current €10B CGM market. QuLab Medical's initial market penetration will focus on continuous lactate monitoring (CLM) intended for elite sports teams and high-performance athletes, leveraging their influence to drive broader adoption.

- **What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans**

QuLab Medical clinical trial for its CLM product is ongoing. The company is seeking additional funding to finalize this study towards regulatory submission.